NASDAQ: BBOTBridgebio Oncology Therapeutics Inc Stock
$8.94-0.51 (-5.4%)
Updated Aug 29, 2025
BBOT Price
$8.94
Fair Value Price
N/A
Market Cap
$546.23M
52 Week Low
$8.50
52 Week High
$12.50
P/E
-0.02x
P/B
-2.4x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$106.51M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.13
Operating Cash Flow
-$97M
Beta
0.02
Next Earnings
Sep 3, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BBOT Overview
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BBOT's potential to beat the market
- BBOT doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BBOT
RankedUnranked of 482
RankedUnranked of 482
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.88 | A | |
| $38.85 | A | |
| $306.05 | A |
Be the first to know about important BBOT news, forecast changes, insider trades & much more!
BBOT News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BBOT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BBOT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BBOT is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
BBOT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more BBOT due diligence checks available for Premium users.
Valuation
BBOT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.02x
Industry
-102.1x
Market
35.25x
BBOT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.4x
Industry
4.56x
BBOT's financial health
Profit margin
Revenue
$0.0
Net Income
-$28.4M
Profit Margin
0%
BBOT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$151.3M
Liabilities
$29.8M
Debt to equity
-0.13
BBOT's short-term assets ($142.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BBOT's short-term assets ($142.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BBOT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BBOT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$42.2M
Investing
$25.0M
Financing
$18.6M
BBOT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BBOT vs Biotech Stocks
Bridgebio Oncology Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.